重复注入胺对治疗耐药性抑郁症和相关代谢物变化的急性和长期影响
Hitoshi Sakurai1, Daiki Setoyama2, Takahiro A Kato3
1Department of Neuropsychiatry, Kyorin University School of Medicine, Tokyo, Japan.
Psychiatry and clinical neurosciences
|July 15, 2025
概括
重复注入胺在治疗耐药性抑郁症 (TRD) 中显示出快速抗抑郁作用,但持续缓解是有限的. 早期的3-基酸盐变化可以预测治疗反应.
科学领域:
- 神经科学是一个神经科学.
- 精神病学是一个精神病学.
- 代谢学 代谢学 代谢学
背景情况:
- 耐治疗抑郁症 (TRD) 是一个重大的临床挑战.
- 胺是TRD的新兴治疗选择.
- 鉴定基他胺反应的生物标志物至关重要.
研究的目的:
- 评估在TRD患者中重复注入胺的急性和持续抗抑郁作用.
- 识别早期的代谢变化,预测治疗结果.
- 探索代谢组分析在指导TRD治疗中的潜力.
主要方法:
- 一项涉及30名TRD患者的开放性研究,在两周内接受了四次静脉胺注射 (0.5 mg/kg).
- 在多个时间点评估临床结果 (MADRS分数),包括12个月的随访.
- 输注前和输注后测量了血代谢物水平,统计分析将早期代谢物变化与长期结果联系起来.
主要成果:
- 胺注射显著降低了MADRS得分,第四次注射后的缓解率为26.7%.
- 在12个月后,13.3%的参与者观察到持续缓解.
- 第一次输液后增加的3基酸盐水平预测了第4次输液和12个月后续观察时MADRS得分的更大改善.
结论:
- 在TRD中,重复注入胺会产生快速但往往不持续的抗抑郁作用.
- 3-基酸盐显示为胺治疗反应的早期预测生物标志物具有前途.
- 个性化治疗策略,包括胺注射和生物标志物监测,可能会改善患者的治疗结果.
更多相关视频
相关概念视频
Desensitization and Tachyphylaxis
2.2K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
2.2K
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
302
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
302
Electroconvulsive Therapy
200
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
200
Long-term Depression
2.6K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
Calcium Ion Concentration Mechanism
If over...
2.6K
Antidepressant Drugs: MAOIs and Other Agents
372
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
372
Sedatives and Hypnotics Drugs: Miscellaneous Agents
245
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
245


